Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Abstract Introduction This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. Methods HUR-BIO (Hacettepe University Rheumatology Biologic Registr...

Full description

Bibliographic Details
Main Authors: Emine Duran, Zeynep Ozge Ozturk, Emre Bilgin, Yahya Büyükaşık, Omer Dizdar, Gozde Kubra Yardimci, Bayram Farisogullari, Zehra Özsoy, Gizem Ayan, Gullu Sandal Uzun, Mustafa Ekici, Erdinc Unaldi, Levent Kilic, Ali Akdoğan, Omer Karadag, Şule Apraş Bilgen, Sedat Kiraz, Umut Kalyoncu, Ali Ihsan Ertenli
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Rheumatology and Therapy
Subjects:
Hematologic malignancy
TNF inhibitors
Spondyloarthritis
Rheumatoid arthritis
Psoriatic arthritis
Online Access:https://doi.org/10.1007/s40744-023-00563-z

Internet

https://doi.org/10.1007/s40744-023-00563-z

Similar Items